Skip to content

Global access and outcome disparity

TL;DR — Geography is a survival determinant because it changes stage at diagnosis, referral time, continuity, specialist access and treatment completion. In the 149-country cohort, enucleation was available everywhere and intravenous chemotherapy to 98.8%, yet cT4 presentation and three-year mortality rose steeply as national income fell. Therefore, treatment availability cannot serve as a proxy for delivered care. Delay and abandonment need separate denominators and interventions.

Decision-relevant evidence

  • Three-year survival was 99.5% (95% CI 98.8–100.0), 91.2% (89.5–93.0), 80.3% (78.3–82.3) and 57.3% (52.1–63.0) across high-, upper-middle-, lower-middle- and low-income strata (PMID 35839812).

  • cT4 prevalence was 0.8% (5/636), 5.4% (55/1,027), 19.7% (342/1,738) and 42.9% (196/457) across the same strata, and low-income residence carried adjusted mortality HR 16.67 (95% CI 4.76–50.00) (PMID 35839812).

  • Essential treatments were nominally available: enucleation for all enrolled children and intravenous chemotherapy for 98.8% (4,014/4,064) (PMID 35839812). Availability and outcome are therefore not the same variable.

  • The 2017 cross-sectional study of 4,351 new patients from 153 countries makes the gradient sharper still: median age at diagnosis was 14.1 months in high-income versus 30.5 months in low-income countries; 656 of 666 high-income patients (98.5%) had intraocular disease with metastasis in 0.3%, against 256 of 521 low-income patients (49.1%) with extraocular disease and 94 of 498 (18.9%) with metastasis. Advanced disease remained far more likely in low-income countries after adjusting for age (OR 17.92, 95% CI 12.94–24.80 versus upper-middle-income and high-income countries) (Fabian 2020, PMID 32105305).

  • That study also records an artefact worth stating plainly: the proportion with a family history of retinoblastoma was smaller in low-income countries, which the authors attribute to survivors not reaching childbearing age. Family history is therefore a biased ascertainment tool where mortality is high (PMID 32105305).

  • Service availability has improved but stayed income-concentrated. In 2024, 438 centres in 145 countries reported pathology available in 143 countries (98.6%), MRI in 128 (88.3%) and genetic testing in only 74 (51.0%); intravenous chemotherapy was available in 139 countries (95.9%), intravitreal chemotherapy in 101 (69.7%) and intra-arterial chemotherapy in 69 (47.6%). Among 246 centres assessed in both 2017 and 2024, proportional availability rose for every modality — most for genetic testing, intravitreal chemotherapy and cryotherapy — but concentration indices showed availability still concentrated in higher-income settings for everything except pathology and intravenous chemotherapy. Forty-nine countries had no identified retinoblastoma centre at all (Global Retinoblastoma Study Group 2026, PMID 42463304).

  • In India, 44% of total lag arose before first consultation while diagnosis and treatment-initiation intervals together accounted for 57% after rounding; the authors' own conclusion is that parental lag is the single largest contributor and should be addressed through community awareness and routine red-reflex checks at immunisation contacts. Both readings are supported by the same data, and neither licenses blaming families: the lag also correlated with lower socio-economic status (P = 0.006), greater distance from the treating centre (P = 0.001) and first consultation with a non-specialist (P = 0.001) (Das 2025, PMID 40719713).

  • Ethiopian hospital data show what a late-presenting cohort looks like: of 217 newly diagnosed children, 40.1% were extraocular at presentation, 73.3% of the intraocular cases were group D or E, and 54.4% of enucleated eyes had high-risk pathology. Median lag was 5 months for intraocular versus 12 months for extraocular disease (P < 0.001), and median age at presentation was 29 months (Sherief 2022, PMID 36938376).

  • Where children enter care, they may still not complete it: abandonment reached 38.5% at IRSS stage III and 46.6% at stage IV in one resource-limited extraocular cohort, and every stage IV patient died at a median follow-up of three months (Pant 2017, PMID 29337595). Abandonment is a treatment-completion failure, not a diagnostic one, and needs different interventions from awareness campaigns.

  • Disparity persists inside the treated population after adjustment for stage and treatment. Among 1,426 primarily enucleated patients, multivariate Cox analysis adjusting for AJCC pT stage and adjuvant therapy still found 6.8-fold risk of orbital recurrence in Hispanic compared with Caucasian patients (P = 0.010) and 3.2-fold risk of metastasis-related death in Hispanic and Asian patients (P = 0.028 and P = 0.038) (Kaliki 2025, PMID 39731391). Race here is a proxy for health-system and referral factors the dataset does not measure, and the authors do not claim a biological mechanism.

  • Programme-level intervention has measurable but modest effects: across 55 funded paediatric-cancer projects in low- and middle-income countries, estimated five-year survival rose by a median of 5.1% (range −1.5% in Venezuela to 17.5% in Ukraine) between 2006 and 2016, with the African Retinoblastoma Network scaled from a Mali demonstration project to referral centres in five sub-Saharan countries (Howard 2018, PMID 29726390).

  • Diffusing high-technology globe salvage does not by itself close the survival gap, and its opportunity cost is contested in exactly the settings with the worst survival (Honavar 2023, PMID 36727311; Chintagumpala 2019, PMID 31195906).

Clinical and research frame

Domain Operational meaning Evidence boundary
Recognition Family/community sees leukocoria Awareness and access to first contact
Referral First clinician to specialist Training, distance, transport
Diagnosis EUA/imaging/pathology capacity Specialist network
Start Time from diagnosis to treatment Funding and scheduling
Completion Abandonment/toxicity/interruption Navigation and social protection
Survivorship Genetics and late-effects access Long-term continuity

Interpretation rules

  • Keep the child-level endpoints of survival and metastasis separate from the eye-level endpoint of globe salvage.

  • Report initial stage, laterality, heritability, prior treatment and follow-up; otherwise comparisons are not transportable.

  • A retrospective eye series estimates performance in selected eyes; it does not establish superiority over another route.

  • Absence of metastasis in a small series is a safety observation, not proof that risk is zero.

  • Treatment-era effects matter because external-beam radiotherapy, systemic chemotherapy, IAC and intravitreal therapy create different late-risk profiles.

  • Income stratum and access are effect modifiers, not background descriptors (Global Retinoblastoma Study Group 2022, PMID 35839812).

Evidence register

The following records were each retrieved live from PubMed E-utilities on 2026-09-01 and re-fetched live during the independent audit on the same date. Every identifier below resolved, and its author, year, journal and title matched the citation as written. Inclusion records the evidence base for this page; a register entry asserts that the record exists and is on topic, not that it supports a specific effect estimate.

PMID Year Study or review Role in this page
35839812 2022 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Topic-resolved source (Global 2022, PMID 35839812)
40719713 2025 Lag time for diagnosis and treatment in 1120 retinoblastoma children: Analysis from InPOG-RB-19-01. Topic-resolved source (Das 2025, PMID 40719713)
29337595 2017 Outcome of extraocular retinoblastoma in a resource limited center from low middle income country. Topic-resolved source (Pant 2017, PMID 29337595)
29726390 2018 The My Child Matters programme: effect of public-private partnerships on paediatric cancer care in low-income and middle-income countries. Topic-resolved source (Howard 2018, PMID 29726390)
27189421 2015 Retinoblastoma. Topic-resolved source (Dimaras 2015, PMID 27189421)
37667345 2023 Retinoblastoma: present scenario and future challenges. Topic-resolved source (Byroju 2023, PMID 37667345)
38615905 2024 Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Topic-resolved source (Zhou 2024, PMID 38615905)
31195906 2019 Retinoblastoma in Low- and Middle-Income Countries. Topic-resolved source (Chintagumpala 2019, PMID 31195906)
26023180 2016 Retinoblastoma. Topic-resolved source (Ortiz 2016, PMID 26023180)
22414599 2012 Retinoblastoma. Topic-resolved source (Dimaras 2012, PMID 22414599)
36727311 2023 Intraarterial chemotherapy for retinoblastoma in low and lower-middle-income countries - Can we break the barriers? Topic-resolved source (Honavar 2023, PMID 36727311)
35820112 2022 Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). Topic-resolved source (Dunkel 2022, PMID 35820112)
30385881 2019 Retinoblastoma in Asia. Topic-resolved source (Jain 2019, PMID 30385881)
36756097 2022 Retinoblastoma: Poster-Child Tumor of the Low-Middle Income Countries (LMICs)!!! Topic-resolved source (Ramanathan 2022, PMID 36756097)
8199450 1993 Retinoblastoma. Topic-resolved source (Abramson 1993, PMID 8199450)
1331956 1992 [Retinoblastoma]. Topic-resolved source (Bouffet 1992, PMID 1331956)
35093203 2022 Retinoblastoma outcomes: a global perspective. Topic-resolved source (Finger 2022, PMID 35093203)
33583507 2021 Neonatal Retinoblastoma. Topic-resolved source (Lin 2021, PMID 33583507)
38263682 2024 Global retinoblastoma studies: A review. Topic-resolved source (Vempuluru 2024, PMID 38263682)
32105305 2020 Global Retinoblastoma Presentation and Analysis by National Income Level. Topic-resolved source (Global 2020, PMID 32105305)
29737052 2018 Retinoblastoma for Pediatric Ophthalmologists. Topic-resolved source (AlAli 2018, PMID 29737052)
20679076 2010 Challenging the global retinoblastoma survival disparity through a collaborative research effort. Topic-resolved source (Dimaras 2010, PMID 20679076)
35412907 2022 Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies. Topic-resolved source (Tu 2022, PMID 35412907)
32824373 2020 Retinoblastoma: Etiology, Modeling, and Treatment. Topic-resolved source (Kaewkhaw 2020, PMID 32824373)
35972479 2022 Retinoblastoma Especially Deadly in Children in Low-Income Countries. Topic-resolved source (Larkin 2022, PMID 35972479)
24422571 2014 Retinoblastoma: saving life with vision. Topic-resolved source (Abramson 2014, PMID 24422571)
35584909 2023 Intra-arterial chemotherapy for retinoblastoma. Topic-resolved source (Carnevale 2023, PMID 35584909)
22106703 2011 Trilateral retinoblastoma. Topic-resolved source (Limn 2011, PMID 22106703)
22337189 2012 Retinoblastoma. Topic-resolved source (Mehta 2012, PMID 22337189)
29321667 2018 The management of retinoblastoma. Topic-resolved source (Fabian 2018, PMID 29321667)
26969537 2016 Retinoblastoma: An update. Topic-resolved source (Delhiwala 2016, PMID 26969537)
40471757 2025 Managing retinoblastoma in 2025. Topic-resolved source (Ramos-Dávila 2025, PMID 40471757)
41645972 2025 Orbital myiasis in neglected orbital retinoblastoma. Topic-resolved source (Panda 2025, PMID 41645972)
40926918 2025 Retinoblastoma in Dandy-Walker Syndrome. Topic-resolved source (Lomi 2025, PMID 40926918)
38609685 2024 Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines. Topic-resolved source (Meel 2024, PMID 38609685)
30350021 2019 Expression profiles and prognostic value of miRNAs in retinoblastoma. Topic-resolved source (Delsin 2019, PMID 30350021)
41280625 2025 Retinoblastoma management in China: clinical challenges. Topic-resolved source (Wang 2025, PMID 41280625)
34359552 2021 Natural History of Untreated Retinoblastoma. Topic-resolved source (Zhao 2021, PMID 34359552)
31827335 2019 Head and Eye Trauma Before Retinoblastoma Diagnosis. Topic-resolved source (Chen 2019, PMID 31827335)
18762512 2008 Retinoblastoma: one world, one vision. Topic-resolved source (Rodriguez-Galindo 2008, PMID 18762512)
42463304 2026 Global retinoblastoma service availability in 2024 and equity trends since 2017. Added by audit 2026-09-01 (Global Retinoblastoma Study Group 2026, PMID 42463304)
36938376 2022 Clinicopathological Presentation of Retinoblastoma in Ethiopia. Added by audit 2026-09-01 (Sherief 2022, PMID 36938376)
39731391 2025 Impact of Race on the Outcomes of Retinoblastoma Treated With Primary Enucleation: A Global Study of 1426 Patients. Added by audit 2026-09-01 (Kaliki 2025, PMID 39731391)

Source chronology

Era marker PMID What the record contributes
1992 1331956 [Retinoblastoma]. (Bouffet 1992, PMID 1331956)
1993 8199450 Retinoblastoma. (Abramson 1993, PMID 8199450)
2008 18762512 Retinoblastoma: one world, one vision. (Rodriguez-Galindo 2008, PMID 18762512)
2010 20679076 Challenging the global retinoblastoma survival disparity through a collaborative research effort. (Dimaras 2010, PMID 20679076)
2011 22106703 Trilateral retinoblastoma. (Limn 2011, PMID 22106703)
2012 22337189 Retinoblastoma. (Mehta 2012, PMID 22337189)
2012 22414599 Retinoblastoma. (Dimaras 2012, PMID 22414599)
2014 24422571 Retinoblastoma: saving life with vision. (Abramson 2014, PMID 24422571)
2015 27189421 Retinoblastoma. (Dimaras 2015, PMID 27189421)
2016 26023180 Retinoblastoma. (Ortiz 2016, PMID 26023180)
2016 26969537 Retinoblastoma: An update. (Delhiwala 2016, PMID 26969537)
2017 29337595 Outcome of extraocular retinoblastoma in a resource limited center from low middle income country. (Pant 2017, PMID 29337595)
2018 29321667 The management of retinoblastoma. (Fabian 2018, PMID 29321667)
2018 29726390 The My Child Matters programme: effect of public-private partnerships on paediatric cancer care in low-income and middle-income countries. (Howard 2018, PMID 29726390)
2018 29737052 Retinoblastoma for Pediatric Ophthalmologists. (AlAli 2018, PMID 29737052)

Evidence limitations

  • Most intraocular treatment evidence is observational, single-centre and reported per eye; bilateral eyes within one child are statistically correlated.

  • Classification and treatment changed over time, producing stage migration and confounding by indication.

  • Rare metastatic and late-effect outcomes require multinational cohorts and decades of follow-up.

  • Verification is abstract-level. Every claim on this page was checked against the abstract of the record it cites during the independent audit on 2026-09-01; where an abstract could not support a claim, the claim was removed or restated as an explicit limit. Claims requiring full text beyond the abstract are not made here.

Open questions

  • Which interval mediates the largest mortality share by setting? The current evidence register defines the design space but does not close the question.

  • Can cash, transport and navigation packages reduce abandonment? The current evidence register defines the design space but does not close the question.

  • Which resource-stratified eye-salvage technologies preserve survival? The current evidence register defines the design space but does not close the question.

References

  1. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet. Global health. 2022;10:e1128-e1140. PMID 35839812
  2. Das S, et al. Lag time for diagnosis and treatment in 1120 retinoblastoma children: Analysis from InPOG-RB-19-01. Indian journal of ophthalmology. 2025;73:1124-1131. PMID 40719713
  3. Pant G, et al. Outcome of extraocular retinoblastoma in a resource limited center from low middle income country. Pediatric hematology and oncology. 2017;34:419-424. PMID 29337595
  4. Howard SC, et al. The My Child Matters programme: effect of public-private partnerships on paediatric cancer care in low-income and middle-income countries. The Lancet. Oncology. 2018;19:e252-e266. PMID 29726390
  5. Dimaras H, et al. Retinoblastoma. Nature reviews. Disease primers. 2015;1:15021. PMID 27189421
  6. Byroju VV, et al. Retinoblastoma: present scenario and future challenges. Cell communication and signaling : CCS. 2023;21:226. PMID 37667345
  7. Zhou M, et al. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2024;13:100058. PMID 38615905
  8. Chintagumpala M. Retinoblastoma in Low- and Middle-Income Countries. Pediatric hematology and oncology. 2019;36:53-54. PMID 31195906
  9. Ortiz MV, et al. Retinoblastoma. Journal of child neurology. 2016;31:227-36. PMID 26023180
  10. Dimaras H, et al. Retinoblastoma. Lancet (London, England). 2012;379:1436-46. PMID 22414599
  11. Honavar SG. Intraarterial chemotherapy for retinoblastoma in low and lower-middle-income countries - Can we break the barriers? Indian journal of ophthalmology. 2023;71:325-326. PMID 36727311
  12. Dunkel IJ, et al. Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40:3839-3847. PMID 35820112
  13. Jain M, et al. Retinoblastoma in Asia. Eye (London, England). 2019;33:87-96. PMID 30385881
  14. Ramanathan S, et al. Retinoblastoma: Poster-Child Tumor of the Low-Middle Income Countries (LMICs)!!! South Asian journal of cancer. 2022;11:279-280. PMID 36756097
  15. Abramson DH, et al. Retinoblastoma. Optometry clinics : the official publication of the Prentice Society. 1993;3:49-61. PMID 8199450
  16. Bouffet E, et al. [Retinoblastoma]. Pediatrie. 1992;47:399-408. PMID 1331956
  17. Finger PT, et al. Retinoblastoma outcomes: a global perspective. The Lancet. Global health. 2022;10:e307-e308. PMID 35093203
  18. Lin FY, et al. Neonatal Retinoblastoma. Clinics in perinatology. 2021;48:53-70. PMID 33583507
  19. Vempuluru VS, et al. Global retinoblastoma studies: A review. Clinical & experimental ophthalmology. 2024;52:334-354. PMID 38263682
  20. Global Retinoblastoma Study Group, et al. Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA oncology. 2020;6:685-695. PMID 32105305
  21. AlAli A, et al. Retinoblastoma for Pediatric Ophthalmologists. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2018;7:160-168. PMID 29737052
  22. Dimaras H, et al. Challenging the global retinoblastoma survival disparity through a collaborative research effort. The British journal of ophthalmology. 2010;94:1415-6. PMID 20679076
  23. Tu J, et al. Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies. Proceedings of the National Academy of Sciences of the United States of America. 2022;119:e2117857119. PMID 35412907
  24. Kaewkhaw R, et al. Retinoblastoma: Etiology, Modeling, and Treatment. Cancers. 2020;12. PMID 32824373
  25. Larkin HD. Retinoblastoma Especially Deadly in Children in Low-Income Countries. JAMA. 2022;328:611. PMID 35972479
  26. Abramson DH. Retinoblastoma: saving life with vision. Annual review of medicine. 2014;65:171-84. PMID 24422571
  27. Carnevale JA, et al. Intra-arterial chemotherapy for retinoblastoma. Journal of neurointerventional surgery. 2023;15:303-304. PMID 35584909
  28. Limn YS, et al. Trilateral retinoblastoma. The Medical journal of Malaysia. 2011;66:156-7. PMID 22106703
  29. Mehta M, et al. Retinoblastoma. Singapore medical journal. 2012;53:128-35; quiz 136. PMID 22337189
  30. Fabian ID, et al. The management of retinoblastoma. Oncogene. 2018;37:1551-1560. PMID 29321667
  31. Delhiwala KS, et al. Retinoblastoma: An update. Seminars in diagnostic pathology. 2016;33:133-40. PMID 26969537
  32. Ramos-Dávila EM, et al. Managing retinoblastoma in 2025. Current opinion in ophthalmology. 2025;36:414-426. PMID 40471757
  33. Panda BB, et al. Orbital myiasis in neglected orbital retinoblastoma. The National medical journal of India. 2025;38:353-354. PMID 41645972
  34. Lomi N, et al. Retinoblastoma in Dandy-Walker Syndrome. Cureus. 2025;17:e89663. PMID 40926918
  35. Meel R, et al. Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines. Indian journal of pediatrics. 2024;91:1166-1176. PMID 38609685
  36. Delsin LEA, et al. Expression profiles and prognostic value of miRNAs in retinoblastoma. Journal of cancer research and clinical oncology. 2019;145:1-10. PMID 30350021
  37. Wang N, et al. Retinoblastoma management in China: clinical challenges. International journal of ophthalmology. 2025;18:2380-2384. PMID 41280625
  38. Zhao J, et al. Natural History of Untreated Retinoblastoma. Cancers. 2021;13. PMID 34359552
  39. Chen R, et al. Head and Eye Trauma Before Retinoblastoma Diagnosis. Cancer management and research. 2019;11:10269-10274. PMID 31827335
  40. Rodriguez-Galindo C, et al. Retinoblastoma: one world, one vision. Pediatrics. 2008;122:e763-70. PMID 18762512
  41. Global Retinoblastoma Study Group. Global retinoblastoma service availability in 2024 and equity trends since 2017. The British journal of ophthalmology. 2026;. PMID 42463304
  42. Sherief ST, et al. Clinicopathological Presentation of Retinoblastoma in Ethiopia. Ocular oncology and pathology. 2022;8:168-174. PMID 36938376
  43. Kaliki S, et al. Impact of Race on the Outcomes of Retinoblastoma Treated With Primary Enucleation: A Global Study of 1426 Patients. Clinical & experimental ophthalmology. 2025;53:421-434. PMID 39731391